Rhythm controller sells 4,643 shares after exercises
Rhythm Pharmaceuticals Corporate Controller & CAO Christopher Paul German reported same-day option exercises and a share sale.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Rhythm Pharmaceuticals Corporate Controller & CAO Christopher Paul German reported same-day option exercises and a share sale. He exercised stock options for an aggregate 4,442 shares of Common Stock at exercise prices of $17.97, $49.23, and $56.69 per share.
On May 15, 2026, he then completed an open-market sale of 4,643 Common Stock shares at an average price of $92.21 per share, leaving 0 shares of Common Stock held directly after the transactions. He continues to hold stock options, including 2,325, 2,701, and 3,713 options from grants made in 2023, 2024, and 2025, subject to the vesting schedules described.
Insider Trade Summary
Exercise and sale activity reported; no spread calculated
Exercise and Sale
7 txns
Insider
German Christopher Paul
Role
Corporate Controller & CAO
Sold
4,643 shs ($428K)
Approx. gross sale proceeds
$428K
Approx. exercise cost
$187K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Options (Right to Buy) | 1,687 | $0.00 | $0.00 |
| Exercise | Stock Options (Right to Buy) | 1,349 | $0.00 | $0.00 |
| Exercise | Stock Options (Right to Buy) | 1,406 | $0.00 | $0.00 |
| Exercise | Common Stock | 1,687 | $56.69 | $96K |
| Exercise | Common Stock | 1,349 | $49.23 | $66K |
| Exercise | Common Stock | 1,406 | $17.97 | $25K |
| Sale | Common Stock | 4,643 | $92.21 | $428K |
Holdings After Transaction:
Stock Options (Right to Buy) — 8,739 contracts (Direct);
Common Stock — 0 shares (Direct)
Footnotes (4)
- F1. Includes an aggregate of 201 shares of Common Stock purchased pursuant to the Rhythm Pharmaceuticals, Inc. Employee Stock Purchase Plan.
- F2. The stock options were granted on February 14, 2025. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.
- F3. The stock options were granted on February 16, 2024. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.
- F4. The stock options were granted on April 4, 2023. The options vest and become exercisable as to 25% of the total shares on March 20, 2024 and, thereafter, as to the remaining 75% of the total shares in twelve equal quarterly installments of 6.25% beginning June 20, 2024 and ending March 20, 2027, subject to the Reporting Person's continued service on each such vesting date.
Key Figures
Shares sold: 4,643 shares
Sale price: $92.21 per share
Options exercised (grant 1): 1,406 shares at $17.97
+5 more
8 metrics
Shares sold
4,643 shares
Common Stock sold in open market at $92.21 on May 15, 2026
Sale price
$92.21 per share
Average price for 4,643 Common Stock shares sold
Options exercised (grant 1)
1,406 shares at $17.97
Common Stock acquired via option exercise
Options exercised (grant 2)
1,349 shares at $49.23
Common Stock acquired via option exercise
Options exercised (grant 3)
1,687 shares at $56.69
Common Stock acquired via option exercise
Common shares after transactions
0 shares
Directly held Rhythm Pharmaceuticals Common Stock
Remaining options grant 2025
2,325 options
Stock Options (Right to Buy) after 1,406 exercised
Remaining options grant 2024
2,701 options
Stock Options (Right to Buy) after 1,349 exercised
Key Terms
open-market sale, Stock Options (Right to Buy), derivative security, Employee Stock Purchase Plan, +1 more
5 terms
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
Stock Options (Right to Buy) financial
"security_title": "Stock Options (Right to Buy)""
derivative security financial
"transaction_code_description": "Exercise or conversion of derivative security""
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
Employee Stock Purchase Plan financial
"purchased pursuant to the Rhythm Pharmaceuticals, Inc. Employee Stock Purchase Plan."
An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.
vesting financial
"The options vest and become exercisable in 16 substantially equal installments"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did RYTM’s Christopher Paul German report on May 15, 2026?
Christopher Paul German reported exercising stock options and selling shares. He exercised options covering 4,442 Rhythm Pharmaceuticals Common Stock shares, then sold 4,643 shares in an open-market transaction, resulting in no Common Stock shares held directly after these transactions.
What stock options did Christopher Paul German exercise in this RYTM Form 4 filing?
He exercised three stock option grants into 1,406, 1,349, and 1,687 Common Stock shares. The respective exercise prices were $17.97, $49.23, and $56.69 per share, reflecting previously granted employee options vesting over time under company compensation plans.
Does the RYTM insider still hold Common Stock after these reported transactions?
After the May 15, 2026 sale, his directly held Common Stock position is reported as 0 shares. The filing shows that all directly owned shares were sold, although he continues to hold stock options that may be exercisable in the future.
What ongoing stock option holdings does the RYTM insider report after exercising options?
Following these exercises, he continues to hold options, including 2,325, 2,701, and 3,713 Stock Options (Right to Buy). These options were granted in 2023, 2024, and 2025 and vest in installments contingent on his continued service with Rhythm Pharmaceuticals.
How were the RYTM stock options in this filing originally granted and vested?
The options were granted in 2023, 2024, and 2025 with time-based vesting. Some vest in 16 equal quarterly installments, while another vests 25% after one year and the remaining 75% in twelve quarterly installments, subject to continued service with the company.
AI-generated analysis. How Rhea-AI works. Not financial advice.
